TABLE 4.
Outcomes of published studies using Ras inhibitors for the treatment of recurrent glioblastoma
| Authors & Year | Study Type & Trial Phase |
No. of Patients |
Prior Treatment | Current Intervention & Regimen |
Radiographic Response |
PFS | OS |
|---|---|---|---|---|---|---|---|
| Tipifarnib | BBB permeability: unknown | ||||||
| Cloughesy et al., 2006 |
Phase II clinical trial, single arm |
67 | at least radiotherapy, did not specify chemotherapy |
tipifarnib | CR (0%), PR (7%) | 9% at 6 mos | NA |
|
| |||||||
| Lonafarnib | BBB permeability: adequate | ||||||
| Yust-Katz et al., 2013 |
Phase Ib clinical trial |
34 | variable, but not w/ lona- farnib or tipifarnib |
lonafarnib + temo- zolomide |
CR (6%), PR (18%), SD (47%), PD (29%) |
38% at 6 mos, median 3.9 mos |
13.7 mos |